Expanded Access to Fosigotifator
Status
Conditions
Cree Leukoencephalopathy
Vanishing White Matter
Treatments
Drug: Fosigotifator
Details and patient eligibility
About
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Fosigotifator prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Sex
All
Volunteers
No Healthy Volunteers
Inclusion and exclusion criteria
Trial contacts and locations
0
Loading...
Central trial contact
ABBVIE CALL CENTER
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2025 Veeva Systems